1-20 of 102
Salomon Manier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S. Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez-Otero
Journal: Blood
Blood blood.2024024582.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Clinical Trials & Observations
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred Garfall
Journal: Blood
Blood blood.2023023616.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Brief Report
Anais Schavgoulidze, Jill Corre, Mehmet Kemal Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean-Marc Schiano de Colella, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini-Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Herve Avet-Loiseau
Journal: Blood
Blood (2024) 144 (2): 201–205.
https://doi.org/10.1182/blood.2023022295
Published: 2024
Includes: Supplemental data
Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Clinical Trials & Observations
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Journal: Blood
Blood (2024) 143 (20): 2029–2036.
https://doi.org/10.1182/blood.2023023597
Published: 2024
Includes: Supplemental data
Journal Articles

How I treat multiple myeloma in geriatric patients

Thierry Facon, Xavier Leleu, Salomon Manier
Journal: Blood
Blood (2024) 143 (3): 224–232.
https://doi.org/10.1182/blood.2022017635
Published: 2024
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Sarah Cayla, Benoit Ferment, Noemie Bigot, Denis Caillot, Ingrid Lafon, Lionel Karlin, Anne Lazareth, Cyrille Touzeau, Xavier Leleu, Niels Moya, Stephanie Harel, Aurore Perrot, Pierre Bories, Laure Vincent, Sylvain Lamure, Mohamad Mohty, Florent Malard, Salomon Manier, Ibrahim Yakoub-Agha, Anne-Marie Stoppa, Gabriel Brisou, Olivier Decaux, Roch Houot, Steven Le Gouill, Jerome Lambert, Thierry Facon, Herve Avet Loiseau, Philippe Moreau, Bertrand Arnulf
Journal: Blood
Blood (2023) 142 (Supplement 1): 2139.
https://doi.org/10.1182/blood-2023-188655
Published: 2023
Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Arthur Bobin, Jerome Lambert, Stéfanie Ragot, Aurore Perrot, Salomon Manier, Lionel Karlin, Denis Caillot, Lotfi Benboubker, Thomas Chalopin, Carla Araujo, Jean Fontan, Thorsten Braun, Clara Mariette, Elodie Scherman, Olivier Decaux, jean Sebastien Blade, Faiza Keddar, Christophe Roul, Mamoun Dib, Jill Corre, Frederique Orsini Piocelle, Laure Vincent, Cyrille Touzeau, Philippe Moreau, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6742.
https://doi.org/10.1182/blood-2023-185792
Published: 2023
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody

Iryna Dekhtiarenko, Iva Lelios, Wolfgang Jacob, Meike Schneider, Martin Weisser, Carmelo Carlo-Stella, Salomon Manier, Simon J. Harrison, Rakesh Popat, Anna Caroline Hasselbalch Riley, Ann-Marie E. Bröske
Journal: Blood
Blood (2023) 142 (Supplement 1): 1948.
https://doi.org/10.1182/blood-2023-177669
Published: 2023
Journal Articles

Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption

Ruben Niesvizky, Bertrand Arnulf, Mohamad Mohty, Ajay K. Nooka, Salomon Manier, Michael Tomasson, Nizar J Bahlis, Donald Irby, Jennifer Hibma, Andrea Viqueira, Eric Leip, Alexander Lesokhin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3384.
https://doi.org/10.1182/blood-2023-182166
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Paula Rodríguez Otero, Krina K. Patel, Noopur S. Raje, Olga Moshkovich, Heather Gerould, Jennifer Devlen, Devender Dhanda, Laurie Eliason, Mark Cook, Mihaela Popa-McKiver, Salomon Manier
Journal: Blood
Blood (2023) 142 (Supplement 1): 2385.
https://doi.org/10.1182/blood-2023-173840
Published: 2023
Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin, Lionel Karlin, Denis Caillot, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoit Bareau, Karim Belhadj Merzoug, Lotfi Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Helene Demarquette, Pierre Feugier, Cécile Sonntag, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Petillon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6724.
https://doi.org/10.1182/blood-2023-186599
Published: 2023
Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Xavier Leleu, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj Merzoug, Adrien Trebouet, Patricia Zunic, Jean Marc Schiano De Colella, Christina Tekle, Marianne Gaucher, Olivier Decaux
Journal: Blood
Blood (2023) 142 (Supplement 1): 7419.
https://doi.org/10.1182/blood-2023-179532
Published: 2023
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 207.
https://doi.org/10.1182/blood-2023-174044
Published: 2023
Journal Articles

Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial

M Hasib Sidiqi, Paolo Corradini, Duncan Purtill, Hermann Einsele, Binod Dhakal, Lionel Karlin, Salomon Manier, Shinsuke Iida, Sebastian Giebel, Simon J. Harrison, Brea Lipe, Abdullah Khan, Jordan M. Schecter, Carolyn Chang Jackson, Tzu-min Yeh, Arnob Banerjee, William Deraedt, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Katherine Li, Diana Chen, Jane Gilbert, Tito Roccia, Man Zhao, Nitin Patel, Erika Florendo, Mythili Koneru, Octavio Costa Filho, Dong Geng, Jesus San Miguel, Kwee Yong
Journal: Blood
Blood (2023) 142 (Supplement 1): 4866.
https://doi.org/10.1182/blood-2023-178778
Published: 2023
Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Arthur Bobin, Cyrille Hulin, Jerome Lambert, Aurore Perrot, Salomon Manier, Lydia Montes, Arnaud Jaccard, Lionel Karlin, Pascal Godmer, Denis Caillot, Thomas Chalopin, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Jacques Delaunay, Claire Dingremont, Alberto Santagostino, Mamoun Dib, Margaret Macro, Mourad Tiab, Kamel Laribi, Emmanuelle Bourgeois Petit, Claire Calmettes, Frederique Orsini Piocelle, Benoit Bareau, Reza Tabrizi, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Jill Corre, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6741.
https://doi.org/10.1182/blood-2023-185699
Published: 2023